indazoles has been researched along with Mesothelioma in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adjei, AA; Allen-Ziegler, K; Esplin, B; Mandrekar, SJ; Marchello, B; Molina, JR; Parikh, K; Tan, AD | 1 |
| Koh, Y; Oyanagi, J; Serizawa, M; Shukuya, T; Watanabe, M; Yamamoto, N | 1 |
| George, TJ; Hromas, R; Jaiswal, AS; Jones, D; Najmunnisa, N; Sidhu, GS; Srinivasan, G; Wilcoxen, K; Williamson, EA | 1 |
| Corson, JM; Eilers, G; Fletcher, JA; Kuang, Y; Li, H; Li, X; Liu, L; Meng, F; Ou, WB; Sheng, Q; Shi, S; Yan, Z; Zhou, H; Zhou, S | 1 |
| Baas, P; Buikhuisen, WA; Griffioen, AW; Korse, CM; Scharpfenecker, M; van Tinteren, H | 1 |
2 trial(s) available for indazoles and Mesothelioma
| Article | Year |
|---|---|
A Phase II Study of Pazopanib in Patients with Malignant Pleural Mesothelioma: NCCTG N0623 (Alliance).
Topics: Aged; Aged, 80 and over; Humans; Indazoles; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Pyrimidines; Sulfonamides | 2020 |
A Randomized Phase II Study Adding Axitinib to Pemetrexed-Cisplatin in Patients with Malignant Pleural Mesothelioma: A Single-Center Trial Combining Clinical and Translational Outcomes.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Cisplatin; Female; Follow-Up Studies; Humans; Imidazoles; Indazoles; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Neoplasm Staging; Pemetrexed; Pleural Neoplasms; Prognosis; Survival Rate | 2016 |
3 other study(ies) available for indazoles and Mesothelioma
| Article | Year |
|---|---|
Hypoxia Inducible Factor-1α Inhibition in Von Hippel Lindau-mutant Malignant Pleural Mesothelioma Cells.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indazoles; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Mutation; Pleural Neoplasms; RNA, Small Interfering; Signal Transduction; Von Hippel-Lindau Tumor Suppressor Protein | 2020 |
Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition.
Topics: Cell Line, Tumor; Clone Cells; DNA Repair; Humans; Indazoles; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Mutation; Phthalazines; Piperazines; Piperidines; Pleural Neoplasms; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Synthetic Lethal Mutations; Tumor Suppressor Proteins; Ubiquitin Thiolesterase | 2017 |
Multipoint targeting of the PI3K/mTOR pathway in mesothelioma.
Topics: Antineoplastic Agents; Butadienes; Cell Cycle; Cell Line, Tumor; Chromones; Drug Screening Assays, Antitumor; Enzyme Activation; Everolimus; Humans; Imidazoles; Indazoles; MAP Kinase Signaling System; Mesothelioma; Molecular Targeted Therapy; Morpholines; Neoplasm Proteins; Nitriles; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinolines; raf Kinases; Receptor Protein-Tyrosine Kinases; RNA Interference; RNA, Small Interfering; Signal Transduction; Sirolimus; Sulfonamides; TOR Serine-Threonine Kinases | 2014 |